top of page


NICE backs Padcev and Keytruda combination around surgery for muscle-invasive bladder cancer
NICE has issued positive final draft guidance for perioperative Padcev and Keytruda in muscle-invasive bladder cancer, potentially expanding NHS treatment access before and after surgery for eligible patients regardless of cisplatin suitability.

nuaxia
5 days ago2 min read


FDA grants full approval to Keytruda and Keytruda Qlex for TMB-high advanced solid tumours with updated biomarker threshold
The FDA has converted Keytruda's tumour-mutational-burden-high solid tumour indication to traditional approval, extending the authorisation to Keytruda Qlex and updating the biomarker threshold.

nuaxia
Oct 232 min read


European Commission approves Keytruda plus Padcev for perioperative treatment of muscle-invasive bladder cancer
The European Commission has authorised Keytruda plus Padcev before and after surgery for adults with resectable muscle-invasive bladder cancer, expanding perioperative treatment options in the EU.

nuaxia
Oct 222 min read


Orion Pharma and Qilu partner on pembrolizumab biosimilar for Europe
Orion Pharma and Qilu Pharma Europe have entered a European commercialisation agreement for a proposed intravenous pembrolizumab biosimilar.

nuaxia
Oct 72 min read


STADA and SBP Group partner on Keytruda biosimilar and up to three additional biosimilar programmes
STADA and SBP Group have launched a strategic biosimilars partnership beginning with a proposed Keytruda biosimilar and providing a framework for up to three additional programmes.

nuaxia
Sep 292 min read


Cipla licenses Qilu's Keytruda biosimilar for the US
The agreement gives Cipla exclusive US commercialisation rights to Qilu Pharmaceutical's pembrolizumab biosimilar candidate QL2107, referencing Keytruda.

nuaxia
Sep 42 min read


European Commission approves Trodelvy plus Keytruda for first-line PD-L1-positive metastatic triple-negative breast cancer
The approval establishes Trodelvy-based treatment across PD-L1 status in first-line metastatic TNBC in Europe, following the earlier authorisation of Trodelvy monotherapy for patients not eligible for PD-1/PD-L1 inhibitors.

nuaxia
Aug 252 min read


CHMP backs Trodelvy plus Keytruda for first-line PD-L1-positive metastatic breast cancer
If authorised, the combination would add an antibody-drug conjugate-based first-line option for eligible European patients with unresectable locally advanced or metastatic triple-negative breast cancer.

nuaxia
Jul 272 min read


FDA Approves MSD’s Keytruda Combinations with Padcev for Muscle-Invasive Bladder Cancer
The approvals expand the use of Keytruda and Keytruda Qlex alongside Padcev into the perioperative treatment setting for adults with muscle-invasive bladder cancer.

nuaxia
Jul 134 min read


FDA backs Merck’s dual-pronged push in kidney cancer with Welireg–Keytruda combo approval
The US Food and Drug Administration (FDA) has approved a combination regimen of Merck & Co.’s Keytruda (pembrolizumab) and Welireg (belzutifan).

nuaxia
Jun 152 min read


MSD Secures European Approval for Keytruda Combination Therapy in Ovarian Cancer
Keytruda now approved across EU for PD-L1-positive platinum-resistant ovarian, fallopian tube, and primary peritoneal carcinoma.

nuaxia
Apr 81 min read
bottom of page